Shanghai Fosun Pharmaceutical (600196.SH) subsidiary's nitroglycerin injection receives registration approval.

Shanghai Fosun Pharmaceutical (600196.SH) announced that its controlling subsidiary, Chongqing Medfriend Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Sodium Nitroprusside Injection. The approved indications for this product include: (1) emergency reduction of blood pressure in hypertensive emergencies such as hypertensive crisis, hypertensive encephalopathy, malignant hypertension, and paroxysmal hypertension before and after surgery for pheochromocytoma. It can also be used for controlled hypotension during surgical anesthesia; (2) acute heart failure, including acute pulmonary edema, and is also used for acute heart failure in cases of acute myocardial infarction or acute valve (mitral or aortic valve) regurgitation.